PRKAA2 and type 2 diabetes mellitus: Zhou et al. (Li et al., 2020) exhibited that sulforaphane (SFN) treatment protected against type-2-diabetes-induced renal lipotoxicity through AMPKα2-mediated Nrf2 activation and the beneficial effects of SFN were lost in AMPKα2-/- mice (Li et al., 2020).